Alk-Abello AS (WBO:ALKB) Cyclically Adjusted Revenue per Share: €0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:ALKB Alk-Abello AS WBO:ALKB
64 GF Score
Price €29.94
GF Value €27.41
Valuation Fairly Valued
View Full Analysis

What is Alk-Abello AS Cyclically Adjusted Revenue per Share?

Alk-Abello AS WBO:ALKB +1.77% 64 Cyclically Adjusted Revenue per Share is €0.00 as of Mar. 2026. GuruFocus rates WBO:ALKB with a GF Score™ of 64/100 and a GF Value™ of €27.41 (Fairly Valued).

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Alk-Abello AS's adjusted revenue per share for the three months ended in Mar. 2026 was €1.084. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Alk-Abello AS's average Cyclically Adjusted Revenue Growth Rate was 8.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Alk-Abello AS was 8.50% per year. The lowest was 3.00% per year. And the median was 7.45% per year.

As of today (2026-08-10), Alk-Abello AS's current stock price is €29.94. Alk-Abello AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.00. Alk-Abello AS's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Alk-Abello AS was 13.00. The lowest was 2.75. And the median was 7.63.


Alk-Abello AS  (WBO:ALKB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Alk-Abello AS was 13.00. The lowest was 2.75. And the median was 7.63.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Alk-Abello AS Cyclically Adjusted Revenue per Share Related Terms


Alk-Abello AS Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Alk-Abello AS's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alk-Abello AS Cyclically Adjusted Revenue per Share Chart

Alk-Abello AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Alk-Abello AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

WBO:ALKB vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Alk-Abello AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alk-Abello AS Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's Cyclically Adjusted PS Ratio falls into.


WBO:ALKB
64GF Score
Alk-Abello AS WBO:ALKB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alk-Abello AS Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alk-Abello AS's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.084/121.6800*121.6800
=1.084

Current CPI (Mar. 2026) = 121.6800.

Alk-Abello AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.505 100.600 0.611
201609 0.434 100.200 0.527
201612 0.506 100.300 0.614
201703 0.539 101.200 0.648
201706 0.472 101.200 0.568
201709 0.451 101.800 0.539
201712 0.476 101.300 0.572
201803 0.463 101.700 0.554
201806 0.452 102.300 0.538
201809 0.343 102.400 0.408
201812 0.489 102.100 0.583
201903 0.529 102.900 0.626
201906 0.479 102.900 0.566
201909 0.455 102.900 0.538
201912 0.530 102.900 0.627
202003 0.580 103.300 0.683
202006 0.466 103.200 0.549
202009 0.467 103.500 0.549
202012 0.603 103.400 0.710
202103 0.627 104.300 0.731
202106 0.556 105.000 0.644
202109 0.573 105.800 0.659
202112 0.660 106.600 0.753
202203 0.667 109.900 0.738
202206 0.669 113.600 0.717
202209 0.549 116.400 0.574
202212 0.691 115.900 0.725
202303 0.712 117.300 0.739
202306 0.693 116.400 0.724
202309 0.636 117.400 0.659
202312 0.763 116.700 0.796
202403 0.859 118.400 0.883
202406 0.824 118.500 0.846
202409 0.831 118.900 0.850
202412 0.918 118.900 0.939
202503 0.922 120.200 0.933
202506 0.934 120.700 0.942
202509 0.914 121.600 0.915
202512 1.044 121.200 1.048
202603 1.084 121.680 1.084

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.00 mean?
Alk-Abello AS (WBO:ALKB) has a Cyclically Adjusted Revenue per Share of €0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Alk-Abello AS and its competitors.
Is Alk-Abello AS's Cyclically Adjusted Revenue per Share too high?
Alk-Abello AS's current Cyclically Adjusted Revenue per Share is €0.00. Overall, Alk-Abello AS has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Alk-Abello AS's Cyclically Adjusted Revenue per Share of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Alk-Abello AS and its competitors. Alk-Abello AS's current Cyclically Adjusted Revenue per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (WBO:ALKB) is currently considered Fairly Valued. The stock's GF Value™ is €27.41, compared to a current price of €29.94 — trading 9.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.00. Alk-Abello AS's overall GF Score™ is 64/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Alk-Abello AS (WBO:ALKB), the current Cyclically Adjusted Revenue per Share is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alk-Abello AS (WBO:ALKB) Overvalued in 2026?

Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued. The current stock price of €29.94 is trading 9.2% above its estimated GF Value™ of €27.41. GuruFocus considers Alk-Abello AS to be Fairly Valued.

Key valuation signals for WBO:ALKB:

  • Cyclically Adjusted Revenue per Share: €0.00
  • GF Value™: €27.41 vs. price of €29.94 (9.2% above fair value)
  • GF Score™: 64/100

No single metric tells the full story. See the WBO:ALKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alk-Abello AS Business Description

Address Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
64GF Score

Get the complete analysis for WBO:ALKB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.94
Price
€27.41
GF Value